PDE5

Cardiovascular endocrinology

Cardiovascular endocrinology

Cardiologists have taught us how to conduct large and rigorous clinical trials, but now cardiologists are using our endocrine tools! The beta-adrenergic signaling or the renin-angiotensin-aldosterone system, and more recently the SGLT2 inhibitors, are examples of how neuroendocrine control is central to cardiovascular function. In 'endocrine hands', we are taking back such tools to reveal the molecular players involved.

The oligomeric assembly of the phosphodiesterase-5 is a mixture of dimers and tetramers: a putative role in the regulation of function

Background: Phosphodiesterases (PDEs) are a superfamily of evolutionary conserved cyclic nucleotides (cAMP/cGMP) hydrolysing enzymes, components of transduction pathways regulating crucial aspects of cell life. PDE5, one of these families, is the molecular target of several drugs used to treat erectile dysfunction and pulmonary hypertension. Despite its medical relevance, PDE5 macromolecular structure has only been solved for the isolated regulatory and catalytic domains.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma